Abstract:
The purpose of our research was to increase the effectiveness of the therapy of the patients with hypertension and metabolic syndrome. 56 patients with hypertension, and metabolic syndrome were examined. After registration of the baseline data in addition to baseline therapy Quercetinum 40 mg 3 times a day for 2 months was administered to 30 patients (group 1). Basic therapy was administered to 26 patients (group 2). After treatment in group 1, the levels of office systolic and diastolic blood pressure were 7.6 % and 6.9 % (p<0.05), and the average daily systolic and diastolic blood pressure (according to daily blood pressure monitoring) were 8.6 % and 8.1 % (p<0.05) lower than in group 2. In group 1 positive changes in lipid and carbohydrate metabolism were registered. It was found that the decline of tumor necrosis factor-α levels in group 1 were significantly higher (38.6 %, р<0.05) than in group 2 (20.6 %, р<0.05). Group 1 patients showed significantly decreased of malonic dialdehyde (Δ-37.5 % vs Δ-15.7 % in group 2, р<0,05) and increased of superoxide dismutase activity (Δ30.4 % vs 9.0 %, respectively, р<0.05). Thus, addition of Quercetinum to patients with hypertension and metabolic syndrome increases
the efficacy of antihypertensive therapy, positively affects on glucometabolic parameters, plasma levels of tumor necrosis factor-α and antioxidant status.
